BioValues retweeted
*SANOFI IS SAID TO WEIGH TAKEOVER OF US DRUGMAKER INSMED $INSM
$ACET now at $2.40 or $22M market cap vs $100M Sept cash. Going to be real interesting what RA and Orbimed decide to do here. Outside of Lupus, got some potentially desirable early stage in-vivo CAR-T programs
1
5
1,304
$PEPG RA bought 1/3 of offering at $5: investors.pepgen.com/node/95…
2
17
2,827
BioValues retweeted
$PEPG Ra Capital from offering sec.gov/Archives/edgar/data/…
$PEPG
Guggenheim raised the firm's price target on PepGen to $15 from $7 and keeps a Buy rating on the shares. The firm, which is "encouraged" by the transparency and clarity on individual patient level outcomes in the PGN-EDODM1 10 mg/kg data, says a bolstered balance sheet positions the company well to execute on its registrational study during 2027.
$pepg nice opportunity to grab in $3s post data and offering at $5
2
9
2,566
BioValues retweeted
Cantor reiterated an Overweight rating on $LXEO and said--One-time gene therapy LX2020's showing of 80% mean reduction in non-sustained ventricular tachycardia (NSVT) far exceeds the ~30% provided by current pharmacological standard of care and what we believe to be the market's bar-and significantly derisks eventual accelerated approval as we anticipate this measure to be the primary endpoint of the upcoming pivotal study.
[TYNA RCKT [BIIB LRMR PTCT DSGN SLDB NBIX VYGR]]
Safety with high dose LX2020 presented no surprises.
Together with LX2006, in pivotal development for Friedreich ataxia, we see LXEO as possessing two assets that each offer line of sight to $1B+ sales potential for unmet patient populations that are genetically-defined and clinically-identifiable.
We had already viewed the shares as trading at a significant discount to the FA opportunity alone; today's news appears to put that discount into even sharper relief. We are buyers.
Cantor reiterated $LXEO Overweight-$35 and said that it Sees a High PoS for the FA Pivotal Trial (2H27 guide) hitting on Deepened Conviction.
[BIIB LRMR PTCT]
Cantor said in its note:
Topline data from SUNRISE-FA 2, the pivotal trial evaluating LX2006 (AAVrh10-based gene therapy) for Friedreich's ataxia (FA), are guided for 2H27 and represent a major upcoming catalyst for LXEO shares.
Investor debate has centered on the PoS of this trial, particularly given that the trial is powered around a >= 15% LVMI treatment effect, while a ≥10% threshold is considered clinically meaningful.
Lexeo has conducted analyses supporting a ~99% probability of achieving ≥15% effect size informed by the Phase 1/2 data and additional natural-history and CLARITY-FA data not available to the public.
This has prompted us to go a step further and independently assess the trial's PoS and deepen our conviction ahead of the readout.
The punchline is that our analysis also supports a high PoS for the pivotal trial, increasing our conviction ahead of this major catalyst.
BioValues retweeted
$LXEO large unmet need here ir.lexeotx.com/static-files/…
$LXEO Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment
LX2020 generally well tolerated across 10 participants with no clinically significant complement activation
U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020
Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028
Company to host webcast today at 8:00 AM ET
$lxeo Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval.
12
1,776
BioValues retweeted
$LXEO High-dose PKP2-ACM therapy resulted in 80% reduction in NSVT (!!!), where 20-30% represents current therapy and 35-40% clinically meaningful for their gene therapy. Strong result showing meaningful deepening, just as management suspected it would 💪
ir.lexeotx.com/news-releases…











